Bio-Research.AI (formerly Efortless Update)’s Post

[Clinical Trials] Applied Therapeutics, Inc. reports phase 3 trial results of AT-007 in SORD deficiency showing reduced sorbitol levels and improved patient-reported outcomes https://lnkd.in/gg96b8w6 CSL Behring B.V. and ABIONYX Pharma's CSL112 fails to meet endpoint in phase 3 AMI trial https://lnkd.in/geXfwXKK Tonix Pharmaceuticals' phase 3 trial of Tonmya achieves primary endpoint in fibromyalgia with reductions in pain and improvements in sleep and fatigue https://lnkd.in/ggYnsuyc Corcept Therapeutics' phase 4 trial of Korlym identifies hypercortisolism in 24% of Cushing's syndrome patients https://lnkd.in/gcXUpvw6 [Deals] Kelonia Therapeutics enters strategic collaboration with and Xyphos Biosciences for oncology CAR-T therapy candidate for $875 M https://lnkd.in/gF3YSD4Q ReCode Therapeutics and Intellia Therapeutics, Inc. sign strategic collaboration to advance gene editing therapy candidate for cystic fibrosis https://lnkd.in/gVrnsA94 Harrow and Apotex Inc. sign license agreement granting Canadian rights to market VERKAZIA for Vernal Keratoconjunctivitis and 4 more ophthalmic drugs https://lnkd.in/gKyvwvgk

Applied Therapeutics reports phase 3 trial results of AT-007 in SORD deficiency showing reduced sorbitol levels and improved patient-reported outcomes

Applied Therapeutics reports phase 3 trial results of AT-007 in SORD deficiency showing reduced sorbitol levels and improved patient-reported outcomes

efortless.bio

To view or add a comment, sign in

Explore topics